Zhiwei Zhang

Zhiwei Zhang


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JJJingbo Jiang
Jingbo Jiang
DHDaniel Hoagland
Daniel Hoagland
JPJoseph A. Palatinus
Joseph A. Palatinus
HHHuamei He
Huamei He
JIJegan Iyyathurai
Jegan Iyyathurai
Robert GourdieRobert Gourdie
Robert Gourdie
Background: α Carboxyl terminus 1 (α CT 1) is a 25–amino acid therapeutic peptide incorporating the zonula occludens‐1 (ZO‐1)–binding domain of connexin 43 (Cx43) that is currently in phase 3 clinical testing on chronic wounds. In mice, we reported that α CT 1 reduced arrhythmias after cardiac injury, accompanied by increases in protein kinase Cε phosphorylation of Cx43 at serine 368. Herein, we characterize detailed molecular mode of action of α CT 1 in mitigating cardiac ischemia‐reperfusion injury. Methods and Results: To study α CT 1‐mediated increases in phosphorylation of Cx43 at serine 368, we undertook mass spectrometry of protein kinase Cε phosphorylation assay reactants. This indicated potential interaction between negatively charged residues in the α CT 1 Asp‐Asp‐Leu‐Glu‐Iso sequence and lysines (Lys345, Lys346) in an α‐helical sequence (helix 2) within the Cx43‐ CT . In silico modeling provided further support for this interaction, indicating that α CT 1 may interact with both Cx43 and ZO ‐1. Using surface plasmon resonance, thermal shift, and phosphorylation assays, we characterized a series of α CT 1 variants, identifying peptides that interacted with either ZO ‐1–postsynaptic density‐95/disks large/zonula occludens‐1 2 or Cx43‐ CT , but with limited or no ability to bind both molecules. Only peptides competent to interact with Cx43‐ CT , but not ZO ‐1–postsynaptic density‐95/disks large/zonula occludens‐1 2 alone, prompted increased pS 368 phosphorylation. Moreover, in an ex vivo mouse model of ischemia‐reperfusion injury, preischemic infusion only with those peptides competent to bind Cx43 preserved ventricular function after ischemia‐reperfusion. Interestingly, a short 9–amino acid variant of α CT 1 (α CT 11) demonstrated potent cardioprotective effects when infused either before or after ischemic injury. Conclusions: Interaction of α CT 1 with the Cx43, but not ZO ‐1, is correlated with cardioprotection. Pharmacophores targeting Cx43‐ CT could provide a translational approach to preserving heart function after ischemic injury.

12 September 2017 in Frontiers in Physiology
Verified
Journal Article
Open access
LMLei Meng
Lei Meng
KLKonstantinos Letsas
Konstantinos Letsas
ABAdrian Marco Baranchuk
Adrian Marco Baranchuk
QSQingmiao Shao
Qingmiao Shao
GTGary Tse
Gary Tse
TLTong Liu
Tong Liu
Fragmented QRS (fQRS) is an electrocardiographic marker related to ventricular fibrillation (VF) and sudden cardiac death (SCD) in various clinical settings. Current data regarding the prognostic significance of fQRS in Brugada syndrome (BrS) are contradictory. This meta-analysis aimed to evaluate the presence of fQRS as a risk stratification tool in BrS. Electronic databases (PubMed, EMBASE and Cochrane Library) were searched until May 2016. Eight observational studies accumulating data on 1,637 BrS patients (mean age: 47±11 years) were included in this meta-analysis. The mean follow-up duration ranged from 21 to 96 months. fQRS was found to be an independent predictor of future arrhythmic events in BrS (RR:3.88, 95% CI 2.26 to 6.65, p < 0.00001) with moderate heterogeneity (I2 = 54%, P=0.03). When analyzing VF as independent end-point, the RR for VF was 3.61, and its 95% CI was 2.11 to 6.18, p < 0.00001. This meta-analysis showed that BrS patients with fQRS are at high risk for future arrhythmic events. The presence of fQRS warrants prospective evaluation as valid arrhythmogenic risk marker in BrS.

30 July 2021 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
YLYifan Li
Yifan Li
YXYumei Xie
Yumei Xie
BLBoning Li
Boning Li
ZXZhaofeng Xie
Zhaofeng Xie
JSJunjun Shen
Junjun Shen
ZZZhiwei Zhang
Zhiwei Zhang
Objective. We reported the 3-year follow-up results of initial clinical experience with the AbsnowTM device, a novel biodegradable occluder for percutaneous closure of atrial septal defect (ASD). Background. The AbsnowTM device is a total biodegradable septal occluder with double-disc poly-L-lactic acid (PLLA) framework and PLLA membranes intergraded into the device to ensure its biodegradability, clinical safety, and efficacy. Methods. Five pediatric patients were enrolled from May to June 2018 in our institution and were followed up for 3 years. A clinical evaluation and transthoracic echocardiography were performed at 24hr, 1 month, 3 months, 6 months, 12 months, and yearly after implantation. Primary endpoints were a composite clinical success, comprising of clinical closure success and safety at the 36-month follow-up evaluation. Secondary endpoints included technical success, procedure success, closure success, and safety at each of the follow-up visits. Results. The median subject age was 3.6 years (range 3.16.5 years). The mean ASD diameter was (13.7±2.9) mm. The median device size was 20mm (range 14 to 24mm). Technical and procedure success was achieved in 100 (5/5) of the patients. At 2-year follow-up, 3 of the 5 patients developed new-onset residual shunts and 2 of them reached a moderate degree. At 3-year follow-up, the residual shunt size increased over time in all the 3 patients, and 1 of them had right ventricular enlargement. All of the 5 patients were free from serious adverse events during the 3-year follow-up, with no device embolization, thromboembolization, or reintervention to the target defect. Conclusion. This 3-year follow-up result of initial experience with the biodegradable AbsnowTM device has demonstrated acceptable safety with no procedural complications. Notably, the high rate of residual shunt significantly affected its efficacy. The long-term safety and efficacy of the device should be further evaluated in a large cohort of patients in future studies.

12 November 2019 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
YLYi‐Fan Li
Yi‐Fan Li
YXYu‐Mei Xie
Yu‐Mei Xie
JCJun Chen
Jun Chen
BLBo‐Ning Li
Bo‐Ning Li
ZXZhao‐Feng Xie
Zhao‐Feng Xie
ZZZhiwei Zhang
Zhiwei Zhang
Objective: To evaluate the feasibility, safety, and effectiveness of a novel, absorbable atrial septal defect (ASD) closure device made of poly‐l‐lactic acid (PLLA) in a swine model of ASD and for the first time in humans.Methods: A preclinical safety study was conducted using a swine model of ASD. In a clinical setting, five pediatric patients underwent ASD closure with the PLLA device with fluoroscopic and transthoracic echocardiography guidance. The procedural results and clinical outcomes at 1 day, 30 days, 3 months, and 6 months after closure were analyzed.Results: The 24‐ and 36‐month follow‐up results of the preclinical study demonstrated that the PLLA device exhibited good endothelialization and degradability in the swine model. In the clinical study, successful device implantation was achieved in all five patients (median age, 3.6 years; range, 3.1–6.5 years). The mean defect size was (13.6 ± 2.7) mm. Follow‐up at 30 days, 3 months, and 6 months was completed in all five cases. The complete defect closure rates with no residual shunt at 30 days, 3 months, and 6 months follow‐up were 60% (3/5), 80% (4/5), and 80% (4/5), respectively. No device dislodgement, significant aortic valve or mitral valve regurgitation, new onset cardiac arrhythmia, or other adverse events were reported.Conclusion: The study results demonstrated that it is feasible to implant the PLLA device for closure of small to medium sized ASDs without significant residual shunts or severe adverse events in humans. The PLLA device exhibited good endothelialization and degradability in the swine model at 24 and 36 months. Further studies to evaluate long‐term safety and effectiveness with the device in a large cohort of patients are warranted.

8 May 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
YLYi-Fan Li
Yi-Fan Li
ZCZe-Wen Chen
Ze-Wen Chen
ZXZhao-Feng Xie
Zhao-Feng Xie
SWShu-Shui Wang
Shu-Shui Wang
YXYu-Mei Xie
Yu-Mei Xie
ZZZhiwei Zhang
Zhiwei Zhang
Atrial septal defect (ASD) is the third most common type of structural congenital heart defect. Patent foramen ovale (PFO) is an anatomical anomaly in up to 25% of the general population. With the innovation of occlusion devices and improvement of transcatheter techniques, percutaneous closure has become a first-line therapeutic alternative for treatment of ASD and PFO. During the past few decades, the development of biodegradable occlusion devices has become a promising direction for transcatheter closure of ASD/PFO due to their biodegradability and improved biocompatibility. The purpose of this review is to comprehensively summarize biodegradable ASD/PFO occlusion devices, regarding device design, materials, biodegradability, and evaluation of animal or clinical experiments (if available). The current challenges and the research direction for the development of biodegradable occluders for congenital heart defects are also discussed.

18 March 2021 in Journal of Interventional Cardiology
Verified
Journal Article
Open access
PDF file
WZWenqian Zhang
Wenqian Zhang
CWChaojie Wang
Chaojie Wang
SLShenrong Liu
Shenrong Liu
LZLingmei Zhou
Lingmei Zhou
JLJunjie Li
Junjie Li
ZZZhiwei Zhang
Zhiwei Zhang
Background. With the rapid development of transcatheter techniques and instruments, transcatheter occlusion for patients with perimembranous ventricular septal defect (pVSD) and aortic valve prolapse (AVP) was constantly being tried, while the efficacy and safety of pVSD with AVP remain controversial. Objective. The aim of this study was to evaluate long-term efficacy and safety of transcatheter occlusion of pVSD with AVP. Methods. We retrospectively analyzed 164 children with pVSD and AVP who underwent transcatheter occlusion between January 2013 and November 2014. AVP was divided into 3 degrees according to right coronary leaflet morphology at end-diastole during aortic root angiography. Patient demographic and clinical data were collected. Results. There were 97 males and 67 females (median age, 40.0 (30.062.7) months; average weight, 16.94±9.02kg). Mild (n=63), moderate (n=89), and severe (n=12) AVP success rates were 93.7, 89.9, and 58.3, respectively. Immediately after procedure, there was no new-onset aortic regurgitation (AR) above trivial degree, residual shunt above mild degree, or complications requiring medication or operation, except for 1 patient who developed transient complete atrioventricular block. During follow-up, 1 mild AVP patient aggravated from mild to moderate AR and 1 moderate AVP patient aggravated from trivial to moderate AR. The new-onset AR in mild, moderate, and severe AVP was 2, 1.8, and 20, respectively. AR disappeared in 17 patients. Residual shunt occurred in 9 patients after procedure, 4 of which disappeared during the follow-up period. No serious complications occurred in any patient during follow-up. Five-year cardiovascular event-free survival rates for mild, moderate, and severe AVP were 89.6, 94.5, and 80.0, respectively. Conclusion. Transcatheter occlusion of pVSD with mild and moderate AVP has a high success rate and few complications, which is safe and effective in long-term follow-up. Transcatheter occlusion of pVSD with severe AVP has low success rates and high AR incidence. Therefore, transcatheter occlusion of pVSD with AVP is recommended for mild to moderate, but not severe, AVP.